A Phase 1/2 interventional study of MK-4208 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase and Chronic Myeloid Leukemia, sponsored by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Recruiting at 54 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment
Part 1 - MK-4208 160 mg once daily (QD) · Part 1- MK-4208 320 mg QD · Part 1- MK-4208 400 mg QD · Part 1- MK-4208 500 mg QD · Part 2 - MK-4208 320 mg QD · Part 2 - MK-4208 500 mg QD · Part 2m - MK-4208 320 mg twice per day (BID) · Part 2m - MK4208 500 mg BID · Part 3 - MK-4208 500 mg QD
Part 1- Dose Level 1 (160 mg) of TERN-701 · Part 1- Dose Level 2 (320 mg) of TERN-701 · Part 1- Dose Level 3 (400 mg) of TERN-701 · Part 1- Dose Level 4 (500 mg) of TERN-701 · Part 2 - Dose 1 (320 mg) · Part 2 - Dose 2 (500 mg)
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 516 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States — 48 open to participants now, 78 under way, 3 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States.
Among the 516 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States, this one is the 20th largest by planned enrollment of the 448 interventional ones that give a count, is one of 14 that started in 2024, is one of 54 in phase 1/2, reaches primary completion later than 60 of the 77 other live ones, and was the 490th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →48 of the 516 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States are open now. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
University of Arizona · Sites in United States
Ages up to 65
Stanford University · Sites in United States
Ages 18–80
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
516 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 172 · Phase 2 277 · Phase 3 31 · Phase 4 7
First in 1992; this study’s year is marked. 14 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 330 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 36 across the 448 interventional studies, 142 across the 44 observational. Of the 409 that completed or were terminated, 195 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
127 of 516 have an industry lead sponsor. The 10 most frequent:
This study is registered under Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), one of the names counted as Merck & Co., Inc. Under that name alone:
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Merck & Co., Inc has 7 studies filed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive — fewer than ten, so there is no comparison to draw.
22 of the studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06423911Phase 3Ascentage Pharma Group Inc.Study of Olverembatinib (HQP1351) in Patients With CML-CP | 2027-06-30 |
| NCT05362773MacroGenicsA Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | 2026-11 |
| NCT01890486Wake Forest University Health SciencesThe Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | 2026-12 |
| NCT06131801Children's Hospital Medical Center, CincinnatiPharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | 2026-12-01 |
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
Add all 22 to your calendar (.ics) → With an account.
Among the 516 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for a new way to treat a blood cancer called chronic myeloid leukemia (CML). Researchers want to learn if MK-4208 (Tern-701) can treat this type of blood cancer.
The goal of this study is to learn about the safety of different doses (amounts) of MK-4208 (Tern-701) and if people tolerate them. Researchers also want to find the highest dose of MK-4208 (Tern-701) that people can tolerate and may work to treat blood cancer.
The criteria were revised on the registry on Oct 15, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Key Inclusion Criteria:
Inclusion Criteria include but are not limited to:
Key Exclusion Criteria:
Exclusion criteria include but are not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive MK-4208 160 mg orally QD.
Drug: MK-4208
Participants receive MK-4208 320 mg orally QD.
Drug: MK-4208
Participants receive MK-4208 400 mg orally QD.
Drug: MK-4208
Participants receive MK-4208 500 mg orally QD.
Drug: MK-4208
Participants receive MK4208 320 mg orally QD.
Drug: MK-4208
Participants receive MK4208 500 mg orally QD.
Drug: MK-4208
Participants receive MK4208 320 mg orally BID.
Drug: MK-4208
Participants receive MK-4208 500 mg orally QD.
Drug: MK-4208
Participants receive MK4208 500 mg orally BID.
Drug: MK-4208
Participants receive MK-4208 500 mg QD
Drug: MK-4208
40 mg and 100 mg oral tablets
Also known as: Tern-701, HS-10382
Part 1: Incidence of Dose Limiting Toxicities (DLTs) During the First Cycle of Intervention
A DLT is any of a prespecified list of adverse events (AEs) of a pre-specified severity that occur during Cycle 1 (up to 28 days) if attributed to the study treatment and not attributed to any other clearly identifiable cause. The percentage of participants who experience DLTs will be reported. Each cycle is 28 days.
Time frame: Up to 28 days
Parts 1, 2m and 3: Number of Participants with at Least One AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding that is determined to be clinically significant by the investigator), symptom, or disease (new or exacerbated) temporally associated with the use of trial intervention. The number of participants with at least one AE will be reported.
Time frame: Up to 3 years
Parts 1, 2m and 3: Number of Participants with at Least One Serious Adverse Event (SAE)
An SAE is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening; Requires in-patient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Other situations determined to be SAEs by the investigator. The number of participants with at least one SAE will be reported.
Time frame: Up to 3 years
Parts 1, 2m and 3: Number of Participants who Discontinued Study Intervention Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding that is determined to be clinically significant by the investigator), symptom, or disease (new or exacerbated) temporally associated with the use of trial intervention. The number of participants who discontinued study intervention due to an AE will be reported.
Time frame: Up to 3 years
Parts 2, 2m and 3: Number of Participants with a Complete Hematologic Response (CHR)
The hematologic response will be evaluated by hematology and differential blood count. A CHR is defined by meeting all the following criteria and lasting for at least 4 weeks: Peripheral blood white blood cell count \< 10 × 109/L ; Peripheral blood platelet count \< 450 × 109/L; No immature cells in peripheral blood, such as myelocytes, promyelocytes, blasts and immature cells, and a basophil level \< 5%; No symptoms or signs of the disease under trial, and the palpable splenomegaly has disappeared. The number of participants with a CHR will be reported.
Time frame: Baseline and up to 3 years
Parts 2, 2m and 3: Number of Participants with a Molecular response (MR)
The MR will be evaluated for all participants, and peripheral blood will be collected and tested for breakpoint cluster region::Abelson (BCR::ABL1/ABLIS) using real-time quantitative polymerase chain reaction performed locally and centrally with validated polymerase chain reaction technology that has a sensitivity of at least 4.5 logs. An MR is defined as follows: MR1: BCR::ABL1IS \> 1% to 10%; MR2: BCR::ABL1IS \> 0.1% to 1%; MR3 (MMR): BCR::ABL1IS \> 0.01% to 0.1%; MR4.0: BCR::ABL1IS \> 0.0032% to 0.01%; MR4.5: BCR::ABL1IS \> 0.001% to 0.0032%, MR5: ≤ 0.001%. The number of participants with a MR will be reported.
Time frame: Baseline and up to 3 years
Parts 2, 2m and 3: Number of Participants who had Best Categorical Shift in BCR-ABL1 Transcript Levels From Baseline
The number of participants who had best categorical molecular response shift on treatment relative to baseline will be reported.
Time frame: Baseline and up to 3 years
Parts 1, 2, 2m and 3: Trough Concentration (Ctrough) of MK-4208 in Plasma
Ctrough is defined as the lowest concentration of study intervention after administration of the dose of intervention and prior to the next dose of intervention. Blood samples will be collected at pre-specified time points to determine the Ctough of MK-4208 in plasma.
Time frame: Pre dose and post dose at predetermined time points up to 3 years
Parts 1, 2, 2m and 3: Maximum Concentration (Cmax) of MK-4208 in Plasma
Cmax is defined as the maximum observed concentration of study intervention in plasma after the administration of a given dose. Blood samples will be collected at pre-specified time points to determine the Cmax of MK-4208 in plasma.
Time frame: Pre dose and post dose at predetermined time points up to 3 years
Parts 1, 2, 2m and 3: Area Under the Plasma Concentration Time Curve (AUC) of MK-4208 in Plasma
AUC is defined as the area of the plasma concentration time curve. It measures the total quantity of active intervention that effectively reaches the systemic circulation after administration of the intervention. Blood samples will be collected at pre-specified time points to determine the AUC of MK-4208 in plasma.
Time frame: Pre dose and post dose at predetermined time points up to 3 years
Parts 1, 2, 2m and 3: Oral Clearance (CL) of MK-4208 in Plasma
CL is defined as the total intervention clearance from plasma. Blood samples will be collected at pre-specified time points to determine the CL of MK-4208 in plasma.
Time frame: Pre dose and post dose at predetermined time points up to 3 years
Parts 1, 2, 2m and 3: Time to Maximum Concentration (Tmax) of MK-4208 in Plasma
Tmax is defined as the maximum time it takes to observe the maximum contration of study intervention in plasma after the administration of a given dose. Blood samples will be collected at pre-specified time points to determine the Tmax of MK-4208 in plasma.
Time frame: Pre dose and post dose at predetermined time points up to 3 years
Part 2: Number of Participants with at Least One AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding that is determined to be clinically significant by the investigator), symptom, or disease (new or exacerbated) temporally associated with the use of trial intervention. The number of participants with at least one AE will be reported.
Time frame: Up to 3 years
Part 2: Number of Participants with at Least One SAE
An SAE is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening; Requires in-patient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Other situations determined to be SAEs by the investigator. The number of participants with at least one SAE will be reported.
Time frame: Up to 3 years
Part 2: Number of Participants who Discontinued Study Intervention Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding that is determined to be clinically significant by the investigator), symptom, or disease (new or exacerbated) temporally associated with the use of trial intervention. The number of participants who discontinued study intervention due to an AE will be reported.
Time frame: Up to 3 years
Part 1: Number of Participants with a CHR
The hematologic response will be evaluated by hematology and differential blood count. A CHR is defined by meeting all the following criteria and lasting for at least 4 weeks: Peripheral blood white blood cell count \< 10 × 109/L ; Peripheral blood platelet count \< 450 × 109/L; No immature cells in peripheral blood, such as myelocytes, promyelocytes, blasts and immature cells, and a basophil level \< 5%; No symptoms or signs of the disease under trial, and the palpable splenomegaly has disappeared. The number of participants with a CHR will be reported.
Time frame: Baseline and up to 3 years
Part 1 : Number of Participants with a MR
The MR will be evaluated for all participants, and peripheral blood will be collected and tested for breakpoint cluster region::Abelson (BCR::ABL1/ABLIS) using real-time quantitative polymerase chain reaction performed locally and centrally with validated polymerase chain reaction technology that has a sensitivity of at least 4.5 logs. An MR is defined as follows: MR1: BCR::ABL1IS \> 1% to 10%; MR2: BCR::ABL1IS \> 0.1% to 1%; MR3 (MMR): BCR::ABL1IS \> 0.01% to 0.1%; MR4.0: BCR::ABL1IS \> 0.0032% to 0.01%; MR4.5: BCR::ABL1IS \> 0.001% to 0.0032%, MR5: ≤ 0.001%. The number of participants with a MR will be reported.
Time frame: Baseline and up to 3 years
Part 1: Number of Participants who had Best Categorical Shift in BCR-ABL1 Transcript Levels From Baseline
The number of participants who had best categorical molecular response shift on treatment relative to baseline will be reported.
Time frame: Baseline and up to 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Nov 2029, 68 months after the start.
Of 26 phase 1/2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 94. This study's planned 68 months is close to that.
How these figures are worked out, and which studies are left out of them.
Part 1 - MK-4208 160 mg once daily (QD) · Part 1- MK-4208 320 mg QD · Part 1- MK-4208 400 mg QD · Part 1- MK-4208 500 mg QD · Part 2 - MK-4208 320 mg QD · Part 2 - MK-4208 500 mg QD · Part 2m - MK-4208 320 mg twice per day (BID) · Part 2m - MK4208 500 mg BID · Part 3 - MK-4208 500 mg QD
Part 1- Dose Level 1 (160 mg) of TERN-701 · Part 1- Dose Level 2 (320 mg) of TERN-701 · Part 1- Dose Level 3 (400 mg) of TERN-701 · Part 1- Dose Level 4 (500 mg) of TERN-701 · Part 2 - Dose 1 (320 mg) · Part 2 - Dose 2 (500 mg)
Part 1 - MK-4208 160 mg once daily (QD) · Part 1- MK-4208 320 mg QD · Part 1- MK-4208 400 mg QD · Part 1- MK-4208 500 mg QD · Part 2 - MK-4208 320 mg QD · Part 2 - MK-4208 500 mg QD · Part 2m - MK-4208 320 mg twice per day (BID) · Part 2m - MK4208 500 mg BID · Part 3 - MK-4208 500 mg QD
Part 1- Dose Level 1 (160 mg) of TERN-701 · Part 1- Dose Level 2 (320 mg) of TERN-701 · Part 1- Dose Level 3 (400 mg) of TERN-701 · Part 1- Dose Level 4 (500 mg) of TERN-701 · Part 2 - Dose 1 (320 mg) · Part 2 - Dose 2 (500 mg)
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Embibatinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) →